Locally Advanced Cervical Cancer: Chemotherapy Before Radiation, Not After
Two recent trials each tested adding more chemotherapy around standard cisplatin-based chemoradiation for locally advanced cervical cancer — one before, one after. One found a real survival benefit. The other found none. The disagreement is about whether that timing difference is the whole story, or a reason to delay radiation that has worked for decades.
Angela K., 36, and her wife are five months into finalizing the adoption of the two siblings they have fostered for the past two years, a process that has already outlasted every estimate the agency gave them, and Angela's diagnosis — FIGO Stage IIB squamous cell cervical cancer, found after months of pelvic pressure she'd attributed to the stress of the adoption paperwork — arrived in the middle of a home-study deadline neither of them wanted to reschedule. Imaging shows a 5cm cervical mass with parametrial extension but no nodal or distant disease, placing her squarely in the population for whom concurrent cisplatin-based chemoradiation has been the unchanged standard of care for more than two decades.
What has changed recently is the evidence around adding more chemotherapy to that standard, and the two most consequential trials point in different directions depending on when the extra chemotherapy is given. OUTBACK tested adding adjuvant carboplatin-paclitaxel after standard chemoradiation was already complete, and found no overall survival benefit — more chemotherapy stacked onto the back end of treatment simply didn't help. INTERLACE tested the opposite sequence: a short induction course of weekly carboplatin-paclitaxel given before chemoradiation starts, and found a real, statistically significant improvement in both progression-free and overall survival compared to chemoradiation alone. The same drug class, added around the same definitive treatment, produced a null result in one position and a positive one in the other — which argues the timing itself is doing real mechanistic work, most plausibly by addressing micrometastatic disease and reducing tumor burden before radiation starts, rather than simply adding more cytotoxic exposure somewhere in the regimen. The complication for Angela specifically is that induction chemotherapy adds roughly six weeks before radiation can begin, in a disease known to proliferate quickly enough that treatment delays have historically been treated as a real risk in their own right — the same six weeks INTERLACE's own trial design accepted as the cost of its benefit. The six weekly cycles the trial actually tested run almost exactly as long as the extension the adoption agency had already granted the couple once before, a coincidence Angela pointed out herself the moment the timeline was laid out for her.
Two trials, two directions, one six-week window
I'd start chemoradiation now. This is a five-centimeter, rapidly proliferating tumor, and treatment delay in cervical cancer has a real, well-documented cost. INTERLACE is a genuinely positive trial, but it's asking us to accept a six-week delay in a disease where delay itself has historically been treated as a risk factor in its own right.
I'd add the induction course. What makes INTERLACE more than just one more positive trial is what it looks like next to OUTBACK: the same drug class, added around the same chemoradiation, failed when given afterward and succeeded when given before — 80% five-year overall survival against 72%, and 72% progression-free against 64%, where OUTBACK moved neither. That's not noise — that's a sequence-dependent effect, most plausibly because induction addresses micrometastatic disease before radiation, and adjuvant chemotherapy arrives too late to matter.
If OUTBACK had also been positive, I'd read INTERLACE as simply confirming that more chemotherapy generically helps. It's the contrast between the two that makes me confident this is really about timing, not dose.
I find the OUTBACK/INTERLACE contrast persuasive too, but I don't think either of you is wrong to hold your position — INTERLACE is recent enough that it isn't universally treated as unconditional standard yet, and the delay risk is real and specific to her tumor. I'd lay both trials out for Angela directly, plainly, and let her weigh the six-week question herself rather than deciding it for her.
The radiation oncologist's delay concern isn't wrong just because INTERLACE was positive — a trial accepting a risk in its design doesn't mean the risk stops being real for the individual patient sitting in front of us.
Agreed, after a direct conversation with Angela about both trials: six weekly cycles of induction carboplatin-paclitaxel, followed by concurrent cisplatin-based chemoradiation as originally planned — she weighed the six-week delay herself and chose to proceed with induction, factoring in her own sense of the tumor's growth rate against the trial's survival benefit.
Not fully agreed among the team even after her decision: the radiation oncologist's discomfort with accepting a treatment delay wasn't resolved by her choice, only set aside by it — logged explicitly as a position that would resurface if her disease showed any sign of progression during the induction window.